- Home
- EXEL vs AEG Comparison
EXEL vs AEG Comparison
Compare EXEL & AEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EXEL | AEG |
|---|---|---|
| Founded | 1994 | 1983 |
| Country | United States | Netherlands |
| Employees | N/A | 15304 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Life Insurance |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 12.1B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | EXEL | AEG |
|---|---|---|
| Price | $43.94 | $8.30 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 21 | 1 |
| Target Price | ★ $46.50 | N/A |
| AVG Volume (30 Days) | 2.1M | ★ 5.4M |
| Earning Date | 05-05-2026 | 02-09-2023 |
| Dividend Yield | N/A | ★ 4.68% |
| EPS Growth | ★ 57.95 | N/A |
| EPS | ★ 2.78 | N/A |
| Revenue | ★ $452,477,000.00 | N/A |
| Revenue This Year | $13.61 | N/A |
| Revenue Next Year | $13.13 | N/A |
| P/E Ratio | $16.05 | ★ $7.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.76 | $6.61 |
| 52 Week High | $48.74 | $8.27 |
Technical Indicators
Market Signals| Indicator | EXEL | AEG |
|---|---|---|
| Relative Strength Index (RSI) | 48.11 | 72.71 |
| Support Level | $43.53 | $7.50 |
| Resistance Level | $44.32 | N/A |
| Average True Range (ATR) | 1.34 | 0.10 |
| MACD | -0.19 | 0.01 |
| Stochastic Oscillator | 11.34 | 96.43 |
Price Performance
Historical ComparisonAbout EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About AEG Aegon Ltd. New York Registry Shares
Aegon is a life insurance and long-term savings business listed in the Netherlands. It was listed on the Amsterdam Stock Exchange in the 1980s and now has mature operations in the United States, the United Kingdom, and four growth markets of Brazil, China, Portugal, and Spain. In recent years, Aegon has been moving through an extensive transformation program during which management has sought to divest noncore operations and improve the risk profile of the business. Financial assets are the parts of the company that are now being run off. Aegon is looking to cycle out of capital-consumptive and volatile earnings products and recycle capital into capital-light and more predictable strategic businesses.